{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:30:27Z","timestamp":1787002227213,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/gt.2017.32","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T10:40:25Z","timestamp":1493808025000},"page":"534-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["New treatments for serious conditions: ethical implications"],"prefix":"10.1038","volume":"24","author":[{"given":"N M P","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C E","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"key":"BFgt201732_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/3030","volume":"20","author":"DK Gavrilov","year":"1998","unstructured":"Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH . Differential SMN2 expression associated with SMA severity. Nat Genet 1998; 20: 230\u2013231.","journal-title":"Nat Genet"},{"key":"BFgt201732_CR2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS . Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007; 22: 946\u2013951.","journal-title":"J Child Neurol"},{"key":"BFgt201732_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0960-8966(94)90090-6","volume":"4","author":"NH Thomas","year":"1994","unstructured":"Thomas NH, Dubowitz V . The natural history of type 1 (severe) spinal muscular atrophy. Neuromuscul Disord 1994; 4: 497\u2013502.","journal-title":"Neuromuscul Disord"},{"key":"BFgt201732_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissle JT . Spinal muscular atrophy. Neurol Clin 2015; 33: 831\u2013846.","journal-title":"Neurol Clin"},{"key":"BFgt201732_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Hontes J, De Vivo DC et al. Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology 2016; 86: 890\u2013897.","journal-title":"Neurology"},{"key":"BFgt201732_CR6","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017\u20133026.","journal-title":"Lancet"},{"key":"BFgt201732_CR7","unstructured":"Biogen Press Release, 2016. US. FDA approves Biogen\u2019s Spinraza (nusinersen), the first treatment for spinal muscular atrophy. Available at: http:\/\/media.biogen.com\/press-release\/neurodegenerative-diseases\/us-fda-approves-biogens-spinraza-nusinersen-first-treatment (accessed on 4 February 2017)."},{"key":"BFgt201732_CR8","unstructured":"FDA News Release, 2016. FDA approves first drug for spinal muscular atrophy. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm534611.htm (accessed on 4 February 2017)."},{"key":"BFgt201732_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"3","author":"M Hache","year":"2016","unstructured":"Hache M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 2016; 3: 899\u2013906.","journal-title":"J Child Neurol"},{"key":"BFgt201732_CR10","unstructured":"Gawande A. Complications: A Surgeon\u2019s Notes on an Imperfect Science. Picador: New York, NY, USA, 2002.."},{"key":"BFgt201732_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1089\/hum.2005.16.1028","volume":"16","author":"LM Arkin","year":"2005","unstructured":"Arkin LM, Sondhi D, Worgall S, Suh LHK, Hackett NR, Kaminsky SM et al. Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum Gene Ther 2005; 16: 1028\u20131036.","journal-title":"Hum Gene Ther"},{"key":"BFgt201732_CR12","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJMsr1610625","volume":"376","author":"MS McCoy","year":"2017","unstructured":"McCoy MS, Carniol M, Chockley K, Urwin JW, Emanuel EJ, Schmidt H . Conflicts of interest for patient-advocacy organizations. N Eng J Med 2017; 376: 880\u2013885.","journal-title":"N Eng J Med"},{"key":"BFgt201732_CR13","unstructured":"Tribble SJ. Drugmakers are turning patients with rare diseases into D.C. lobbyists, Kaiser Health News, 10 April 2017. Available at: http:\/\/khn.org\/news\/drugmakers-help-turn-patients-with-rare-diseases-into-d-c-lobbyists\/ (accessed on 15 April 2017)."},{"key":"BFgt201732_CR14","unstructured":"Richtel M. Therapies that can attack cancer, and organs. New York Times 4 December 2016, pp A1.."},{"key":"BFgt201732_CR15","unstructured":"Shobit S. Biogen, Ionis under fire for Spinraza. Investopedia, 4 January 2017. Available at: http:\/\/www.investopedia.com\/news\/biogen-ionis-under-fire-spinraza-biib-ions\/?ad=dirN&qo=investopediaSiteSearch&qsrc=0&o=40186 (accessed on 5 February 2017)."},{"key":"BFgt201732_CR16","unstructured":"Thomas K. Hefty price set on a new drug that can stunt muscle disease. New York Times 31 December 2016, pp B1.."},{"key":"BFgt201732_CR17","unstructured":"Biogen, SMA 360. Available at: https:\/\/www.spinraza.com\/en_us\/home\/patient-support-services\/biogen-support-program.html (accessed on 5 February 2017)."},{"key":"BFgt201732_CR18","unstructured":"Genetic Information and Nondiscrimination Act, 2008. Pub L No 110-233, 122 Stat 881.."},{"key":"BFgt201732_CR19","unstructured":"US Department of Health and Human Services, 2009. 'GINA' the Genetic Information Nondiscrimination Act of 2008: information for researchers and health care professionals. Available at: https:\/\/www.genome.gov\/pages\/policyethics\/geneticdiscrimination\/ginainfodoc.pdf (accessed on 5 February 2017)."},{"key":"BFgt201732_CR20","unstructured":"Thomas L. The technology of medicine. In: Lives of a Cell: Notes of a Biology Watcher. Viking Press: New York, NY, USA, 1974, pp 31\u201336.."},{"key":"BFgt201732_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ejhg.2014.147","volume":"23","author":"S Lawton","year":"2015","unstructured":"Lawton S, Hickerton C, Archibald AD, McClaren BJ, Metcalfe SA . A mixed methods exploration of families\u2019 experiences of the diagnosis of childhood spinal muscular atrophy. Eur J Hum Genet 2015; 23: 575\u2013580.","journal-title":"Eur J Hum Genet"},{"key":"BFgt201732_CR22","unstructured":"Feudtner C. The want of control: ideas and ideals in the management of diabetes. In: Bittersweet: Diabetes, Insulin, and the Transformation of Illness. UNC Press: Chapel Hill, NC, USA, 2003, pp 121\u2013145.."},{"key":"BFgt201732_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymeth.2015.08.010","volume":"99","author":"HB Baker","year":"2016","unstructured":"Baker HB, McQuilling JP, King NMP . Ethical considerations in tissue engineering research: case studies in translation. Methods 2016; 99: 135\u2013144.","journal-title":"Methods"},{"key":"BFgt201732_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1748-720X.1998.tb01904.x","volume":"26","author":"LR Churchill","year":"1998","unstructured":"Churchill LR, Collins ML, King NMP, Pemberton S, Wailoo K . Genetic research as therapy: implications of 'gene therapy' for informed consent. J Law Med Ethics 1998; 26: 38\u201347.","journal-title":"J Law Med Ethics"},{"key":"BFgt201732_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1056\/NEJMra1411250","volume":"372","author":"C Grady","year":"2015","unstructured":"Grady C . Enduring and emerging challenges of informed consent. N Engl J Med 2015; 372: 855\u2013862.","journal-title":"N Engl J Med"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201732","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/gt201732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:29:10Z","timestamp":1648546150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFgt201732"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.32","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]},"assertion":[{"value":"9 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}